PCI Biotech Holding ASA (OSL:PCIB)

PCI Biotech Holding ASA Income Statement

Financials in millions NOK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Other Revenue	6.74	2.99	4.75	6.27	7.37
Revenue	6.74	2.99	4.75	6.27	7.37
Revenue Growth (YoY)	125.25%	-37.05%	-24.28%	-14.86%	-21.55%
Gross Profit	6.74	2.99	4.75	6.27	7.37
Selling, General & Admin	8.63	9.6	16.44	20.6	13.92
Research & Development	16.06	15.63	44.76	71.71	75.57
Operating Expenses	24.69	25.23	61.2	92.3	89.49
Operating Income	-17.96	-22.24	-56.45	-86.03	-82.12
Interest Expense	-0.06	-0.16	-0.13	-0.09	-0.4
Interest & Investment Income	1.6	2.09	1.24	0.64	1.85
Currency Exchange Gain (Loss)	-	-	-	-2.5	8.5
Other Non Operating Income (Expenses)	-	-0	0.24	-0.41	-0.07
Pretax Income	-16.42	-20.32	-55.1	-88.39	-72.24
Net Income	-16.42	-20.32	-55.1	-88.39	-72.24
Net Income to Common	-16.42	-20.32	-55.1	-88.39	-72.24
Shares Outstanding (Basic)	37	37	37	37	37
Shares Outstanding (Diluted)	37	37	37	37	37
Shares Change (YoY)	-	-	-	0.11%	-0.01%
EPS (Basic)	-0.44	-0.54	-1.48	-2.37	-1.94
EPS (Diluted)	-0.44	-0.54	-1.48	-2.37	-1.94
Free Cash Flow	-13.76	-14.97	-59.04	-68.65	-81.31
Free Cash Flow Per Share	-0.37	-0.40	-1.58	-1.84	-2.18
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-266.59%	-743.85%	-1188.36%	-1371.42%	-1114.55%
Profit Margin	-243.76%	-679.43%	-1159.89%	-1409.07%	-980.44%
Free Cash Flow Margin	-204.28%	-500.67%	-1242.99%	-1094.34%	-1103.56%
EBITDA	-17.65	-22.22	-56.43	-84.11	-80.52
EBITDA Margin	-262.09%	-	-	-	-
D&A For EBITDA	0.3	0.02	0.02	1.92	1.6
EBIT	-17.96	-22.24	-56.45	-86.03	-82.12
EBIT Margin	-266.59%	-	-	-	-
Revenue as Reported	6.74	2.99	4.75	6.27	7.37

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.